<DOC>
	<DOCNO>NCT01635621</DOCNO>
	<brief_summary>The primary purpose multi-centre , double blind-study evaluate clinical response patient moderate severe Cohn 's Disease ( CD ) follow treatment different dos dose regimen Olokizumab , relative placebo .</brief_summary>
	<brief_title>A Phase II Study Assess Efficacy Safety Olokizumab Patients With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subject male female , 18 65 year age Screening Diagnosis CD ( colonic localization ) confirm ( least 12 week prior Screening ) either radiological endoscopic evidence and/or histological examination Colonoscopy perform prior first study medication administration ( Week 0 ) evidence active CD presence ulceration clinical suspicion dysplasia malignancy ( colonoscopy perform informed consent receive , Screening assessment complete ) Moderately severely active CD ( CDAI score : 220 450 , inclusive ) Baseline Female subject must either postmenopausal least 1 year , surgically incapable childbearing , effectively practice acceptable method contraception ( either oral/ parenteral /implantable hormonal contraceptive , intrauterine device barrier spermicide ) Subject diagnosis Ulcerative Colitis Indeterminant Colitis determine investigator Subject obstructive stricture clinical evidence partial complete obstruction Subject active fistula ( fistula secrete spontaneously gentle pressure ) Subject history diverticulitis symptomatic diverticulosis Subject prior exposure antiIL6 agent ( eg , Tocilizumab ) Female subject breastfeeding , pregnant , plan become pregnant study within 24 week follow last dose study drug Subject high risk infection ( eg , subject leg ulcer , indwell urinary catheter , persistent recurrent chest infection , subject permanently bedridden wheelchair bound ) Subject concurrent malignancy history malignancy . Subjects successfully treat remain malignancyfree least 5 year prior Screening may include</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Olokizumab</keyword>
	<keyword>OKZ</keyword>
	<keyword>CDP6038</keyword>
	<keyword>Crohn 's Disease</keyword>
	<keyword>CDAI</keyword>
	<keyword>IBDQ</keyword>
</DOC>